The groundbreaking success of Sildenafil undeniably transformed the drug landscape, but betting in companies strongly reliant on generic versions presents a complex picture. Although early returns were impressive, the expiration of patents and the appearance of less expensive alternatives have weakened the customer base. Consequently, a thorough ev